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Immunoscintigraphy of small-cell lung cancer xenografts with anti neural
cell adhesion molecule monoclonal antibody, 123C3: improvement of
tumour uptake by internalisation
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Departments of 'Tumour Biology and 2Medical Oncology, The Netherlands Cancer Institute (Antoni van Leeuwenhoekhuis),
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Summary The efficacy of three murine monoclonal antibodies (MAbs) for immunoscintigraphy of small-cell
lung cancer (SCLC) xenografts was studied in a Balb/c nu/nu mouse model. These MAbs, 123C3, 123A8 and
MOCl91, belong to cluster 1 of anti-SCLC MAbs and bind to the neural cell adhesion molecule (NCAM) with
similar affinity. After intraperitoneal injection of these MAbs, labelled with 1251, the highest uptake in tumour
tissue was obtained with MAb 123C3. Seven days after administration of this MAb 13.9% of the injected dose
per gram of tumour tissue was retained in the tumour. The corresponding tumour to tissue ratios ranged from
3.97 for blood to 31.03 for colon. The imaging results and the tumour uptake were less favourable for the two
other MAbs, 123A8 and MOCl91 (fractions of injected dose respectively 6.7% and 9.2%), although affinity,
biological activity after labelling and uptake in non-tumour tissues were very similar for all three MAbs. These
results may be explained by the differences in the interaction between the MAbs and the tumour cells. MAb
123C3 is internalised into tumour cells, whereas both other anti-NCAM MAbs are not. Internalisation into
NCI H69 cells was demonstrated in vitro by a radioimmunoassay, confocal laser scanning microscopy and
electron microscopy. The internalised fraction of MAb 123C3 was 22.3% after 24 h, whereas this fraction was
only 7.5% for MAb 123A8. Although the internalised radiolabelled MAbs are usually degraded and
dehalogenated intracellularly, the retained radioactivity is high. Apparently, intracellular degradation of
radiolabelled MAb 123C3 and subsequent secretion of radioactive iodine did not prevent the accumulation of
intracellular radioactivity. In conclusion, accumulation and retention of radioactivity in the tumour tissue, due
to internalisation of radiolabelled MAbs, may improve the results of immunoscintigraphy.
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Clinically, lung cancer is divided into small-cell lung cancer
(SCLC) and non-small-cell lung cancer (NSCLC). SCLC
accounts for about 25% of the cases and is associated with
the worst prognosis of all lung cancers (Yesner, 1985). For
the prognosis and treatment of this type of tumour it is very
important to determine the initial stage of the tumour (Ihde,
1985). Unfortunately, standard staging procedure is very
laborious and inaccurate. In a recent meta-analysis, the best
non-invasive diagnostic technique, computerised tomography
(CT), achieved an accuracy of only 0.80 for the detection of
intrathoracic lesions (Dales et al., 1990). There is clearly a
need for new techniques with a higher sensitivity and
specificity to replace the multitude of diagnostic procedures
used in the initial staging (Ihde, 1985). Monoclonal
antibodies (MAbs) have greatly increased the sensitivity in
detecting bone marrow metastases in SCLC (Ledermann et
al., 1994). Using radiolabelled MAbs in patients with SCLC
(Nelp et al., 1990) distant metastases can be detected by
immunoscintigraphy in 10% of patients with limited disease,
when staged by conventional methods. This finding suggests
that immunoscintigraphy has a higher sensitivity than the
standard staging procedure.
Monoclonal antibodies (MAbs) raised against SCLC are
categorised in clusters by the antigen recognised, according to
an international workshop (Beverley et al., 1988). The MAbs
belonging to cluster 1 bind to the neural cell adhesion
molecule (NCAM) (Moolenaar et al., 1990). Of the existing
NCAM isoforms, NCAM-140 and NCAM-180 are the most
important in SCLC (Moolenaar et al., 1990) and all three
cluster 1 MAbs used in this study recognise these isoforms
(Beverley et al., 1988; Hida et al., 1991). As NCAM is
expressed by all SCLCs, it seems a suitable target for
immunoscintigraphy with these MAbs. The three MAbs
investigated in this study showed similar affinities for NCAM
and were used for radioimmunodetection in a mouse SCLC
xenograft model. We demonstrated that one of the MAbs
that is internalised by the SCLC cells shows a significantly
higher uptake in tumour tissue.
Materials and methods
Cell lines
The NCI H69 cell line (hereafter referred to as H69 cells),
derived from a small cell lung carcinoma, was kindly
provided by Dr D Carney (Gazdar et al., 1980) and was
grown in Dulbecco's modified Eagle medium supplemented
with 1 mm glutamine, 10% fetal calf serum and antibiotics.
This cell line expresses high levels of NCAM when grown in
vitro and as xenografts in nude mice (Rygaard et al., 1992).
Monoclonal antibodies
From a panel of nine cluster 1 MAbs, MAbs 123C3, 123A8
and MOCl91 were selected for this study, on the basis of
their affinity for NCAM and biological activity after labelling
with radioactive iodine (Beverley et al., 1988; Moolenaar et
al., 1990). MAbs 123C3 and 123A8 are IgGI antibodies
raised at our institute against a membrane fraction of a fresh
SCLC specimen. Both MAbs recognise epitopes on the
protein backbone of NCAM close to the attachment site of
the polysialic acid side-chains (Gerardy-Shahn and Eckhardt,
1994) and bind to all NCAM isoforms (Moolenaar et al.,
1990). The tissue distribution of MAb 123C3 in human
tissues was described previously (Schol et al., 1988). MAb
123A8 showed a very similar tissue distribution (DJ Schol
and Ph C Hageman, unpublished data). MAb MOC191 is an
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IgG2a antibody and was kindly provided by Dr LF de Ley,
University Hospital of Groningen. The epitope recognised by
MAb MOC191 is probably located at the third immunoglo-
bulin loop (Hida et al., 1991; Gerardy-Shahn and Eckhardt,
1994). MAb M6/1, and IgGI MAb raised against melanoma
cells, detects a high molecular weight proteoglycan and did
not bind to H69 cells in vitro. All MAbs were affinity purified
from ascitic fluid by protein-A-Sephadex column chromato-
graphy and were eluted with a citrate buffer (pH 4.5) (Jones
et al., 1985).
Antibody labelling
The MAbs were labelled with 1251 (Amersham) using the
chloramine-T method (Hunter and Greenwood, 1962). MAb
(50 jug) was labelled with 50 1iCi of 1251I. Free iodine was
removed from the labelled MAbs by ion-exchange column
chromatography (Dowex G25). For immunofluorescence
experiments the MAbs were labelled with fluorescein
isothiocyanate (FITC) (The and Feltkamp, 1970). Briefly,
1 mg of FITC in dimethylsulphoxide (DMSO) was added to
1 mg of MAb solution in 0.1 M sodium carbonate buffer
(pH 9.5) and incubated overnight at 4°C. Free FITC was
removed over a Dowex G25 column.
Determination of immunoreactivity and in vitro affinity
The immunoreactivity of the MAbs after labelling with 1251,
was assessed according to the method described by Lindmo et
al. (1984) with slight modifications. Serial dilutions of H69
cells in a volume of 200 ul of medium, starting at a cell
concentration of 25 x 106 ml', were incubated with an
equivolume of 1251-labelled MAb in phosphate-buffered
saline (PBS) at a concentration of 50 ng ml-' for 4 h at
4°C. After centrifugation of the cell suspension 200,l of
supernatant was taken and the fraction with and without the
pellet was measured separately in a gamma counter to
determine the amount of bound and free radiolabelled
antibody. From the results the immunoreactive fraction
after iodination was calculated and the immunoreactive
fraction was used to determine the affinity using the
Scatchard method (Lindmo et al., 1984). Briefly, 200 pl of a
cell suspension in medium containing 2.5 x 106 H69 cells was
incubated for 4 h at 4°C with 200 ,Il of a serial dilution of the
radiolabelled MAb in PBS starting at a concentration of
1 ,g ml-'. The amount of bound and free radioactivity was
determined in the same way as described above. After
correction for the immunoreactive fraction the association
constant Ka and the number of binding sites per cell were
calculated.
H69 xenograft model
Human xenografts of H69 cells were established in Balb/c-nu/
nu mice by subcutaneous injection of a cell suspension in PBS
containing 106 cells from in vitro cultures. Within 3 to 4
weeks the tumours reached a volume of 150- 500 mm3
(diameters between 5 mm and 10 mm), suitable for in vivo
studies.
Immunoscintigraphy and biolocalisation
For imaging purposes, groups of five tumour-bearing mice
were injected with radiolabelled MAbs 123C3, 123A8 or
MOC191 and a group of three mice received an injection of
radiolabelled MAb M6/1. A dose varying between 50 and
100 jug of MAb labelled with 50 juCi 1251 was injected
intraperitoneally in each mouse. No potassium iodide was
given to the animals to block the iodine uptake in the thyroid
gland. Images were made on days 2, 4 and 7 after
administration of the radiolabelled MAb. From the images
the counts from the tumour area and the background are
used for quantification of the tumour to background ratio.
The animals were killed after the last image had been made,
and the tissue samples were collected. Wet tissue weight was
determined and the retained radioactivity in the samples was
measured in a gamma counter. Percentages of injected dose
per g of tissue and tumour to tissue ratios for the samples
were calculated from these results.
Internalisation assay
A cell suspension containing 1 x 106 H69 cells in 200 jul of
medium was incubated with 10-20 ,ug ofeach MAb in 200 yl
of PBS, labelled with 50 ,uCi 1251, at 4°C for 60 min. After
removing unbound antibodies by washing the cells three
times in PBS the bound radioactivity was determined in a
gamma counter. Subsequently, the cells were incubated at
0°C or 37°C for various time periods and washed three times
in PBS. The antibodies still present on the cell surface were
removed by incubation of the cells with a buffer containing
0.1 M glycine hydrochloric acid and 0.1 M acetic acid (pH 3)
for 5 min at 0°C (modified from Matzku et al., 1986). After
washing the cells three times in PBS, the remaining
radioactivity was measured. The fraction of internalised
antibody was calculated from the remaining radioactivity
divided by the initially bound radioactivity.
Immunofluorescence
To determine the internalisation of MAb 123C3 by
immunofluorescence, 1 x 106 H69 cells in 1 ml of medium
were incubated with 20 ,ug FITC-labelled MAb 123C3 for
120 min at 37°C. Subsequently, the cells were washed with
PBS and divided into two fractions. One fraction did not
receive any additional treatment and from the other fraction
the surface-bound antibody was removed by treatment with
low-pH buffer as described above to improve visibility of the
intracellular fraction. Then, the cells were attached to a glass
slide coated with poly-L-lysin and fixed with 4% parafor-
maldehyde for 10 min. As control, the same experiment was
done with FITC-labelled MAb 123A8 and with MAb 123C3
in the presence of 50 mM 2-deoxy-D-glucose and 0.01%
sodium azide to block energy-dependent processes, including
internalisation. The cells were imaged with a confocal laser
scanning fluorescence microscope (CLSM) with tomographic
slices of 1 /im thickness.
Electron microscopy
To investigate the internalisation process at the ultrastructur-
al level, a suspension of 1 x 108 H69 cells in 1 ml was
incubated with 1 mg of MAb 123C3 for 24 h. Unbound
MAb was removed by washing the cells three times in PBS.
The cells were fixed with 4% paraformaldehyde in 0.1 M
phosphate buffer for 60 min at room temperature and
embedded in 10% gelatine. After impregnation with 20%
PVP-10 and 1.8 M sucrose for 120 min, the cells were frozen
in liquid nitrogen and 60 nm sections were cut. Subsequently,
the sections were incubated with a 1:40 dilution of rat- anti-
mouse immunoglobulin [RAM/Ig (Nordic)] for 30 min,
followed by incubation a 1:40 dilution of a conjugate of
goat anti-rat immunoglobulin with gold particles [GAR/G10
(Amersham)] for 20 min. After washing, the sections were
covered with 1.5% methylcellulose and 0.3% uranylacetate.
The sections were then examined with a Philips CM10
electron microscope.
Internalisation and degradation
To investigate the fate of the radiolabelled antibody after
internalisation, 2.5 ,ug MAb 123C3 or 123A8 in PBS, labelled
with 25 ,uCi '251, were incubated with 1.4 x 106 H69 cells in
0.5 ml ofculture medium at 4°C for 1 h. After removal of the
unbound MAbs, the total amount of radioactivity in the cell
suspension was determined and the cells were cultured at
37°C. After several periods the culture medium was collected
and the cell suspensions were washed twice in PBS. The
amount of radioactivity in the culture medium and the cell-
associated radioactivity were determined in a gamma counter.Immunoscintigraphy of SCLC xenografts with antl-NCAM MAb 123C3
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Cell-surface bound and intracellular radioactivity were
determined by measuring the cell-associated radioactivity
before and after treatment with low-pH buffer (see above).
The amount of free '25I in the culture supernatant was
dertermined by adding 0.3 ml of 10% trichloroacetic acid
(TCA) and counting the radioactivity in the supernatant after
centrifugation.
Results
We determined the immunoreactive fraction of a panel of
nine cluster 1 MAbs after labelling with '25I according to the
method described by Lindmo et al. (1984). The affinity of the
MAbs for NCAM was determined by Scatchard assay. For
these assays, H69 SCLC cells, expressing high levels of
NCAM, were used (Rygaard et al., 1992). MAbs 123C3,
123A8 and MOC191, which showed the highest immuno-
reactivity and affinity, were selected for further study. The
immunoreactivity of these MAbs were respectively 0.94, 0.68
and 0.85 and the association constants (Ka), corrected for the
immunoreactive fraction, were respectively 1.04, 0.43 and
1.16.109 M-l. The results of 3-5 experiments were shown.
From the results of the Scatchard analysis we calculated that
for each MAb approximately the same numbers of antibody
binding sites were available per H69 cell (5 x 106 per cell).
All three selected MAbs and the control MAb, M6/1,
labelled with 1251, were injected intraperitoneally into mice
bearing H69 xenografts and after 2, 4 and 7 days scintigrams
were made. The images made on days 2 and 4 showed a high
background and a relatively low tumour uptake, whereas the
images made on day 7 had a relatively low background and
higher tumour uptake and were judged to be optimal (Figure
1). These results were confirmed by quantifying the counts
from the images. The mean tumour to background ratio
obtained from the images made with MAb 123C3 showed an
increase from 1.03 on day 2 to 1.99 on day 7, whereas for
MAbs MOC191 and 123A8 the values remained constant at
1.13 and 1.05. Images made with radiolabelled MAb 123C3
showed a higher tumour uptake, resulting in a more distinct
localisation of the tumour than the images produced with
MAbs MOC191 and 123A8. The larger tumours showed a
higher total radioactive count than the smaller ones. Images
made with M6/1, the control antibody, showed no tumour at
all, and a higher background activity than the cluster 1
MAbs. The thyroid gland was not blocked in order to
facilitate the orientation ofthe scan and was clearly visible on
all scintigraphic images.
On day 7 the mice were dissected and the radioactivity in
each tissue was measured. The total radioactive counts varied
greatly with tumour size, but all calculations for tumour
tissue ratios and fraction of injected dose were done on the
counts per g oftissue, which showed less variation. The mean
tumour to tissue ratios 7 days after administration of the
radiolabelled MAbs are shown in Figure 2. The highest
tumour to tissue ratios were observed with MAb 123C3. The
tumour to blood ratio achieved with this MAb was the
highest (3.97, P=0.05, Kruskal-Wallis test), twice the ratio
for MAbs MOC191 and 123A8 (respectively 1.99 and 2.00).
The control MAb, M6/1, showed very low ratios for all
tissues tested (tumour to blood ratio 0.29). The mean
fractions of the injected dose retained in the tissues on day
7 after administration of the MAbs are shown in Figure 3.
MAb 123C3 revealed the highest uptake in the tumour tissue
(13.9%, P=0.04, Kruskal-Wallis test), whereas the values
for MAbs MOC191 and 123A8 were significantly lower
(9.2% and 6.7%). The fraction of the injected dose in the
non-tumour tissues was very similar for all three tested
Figure 1 Immunoscintigrams of H69 xenografts in Balb/c nu/nu mice usin5g three anti-NCAM MAbs and the control antibody M6/
1. The images were made 7 days after intraperitoneal administration of 12 I-labelled MAbs 123C3 (a), MOC191 (b), 123A8 (c) and
MAb M6/1 (d). The images of three mice are shown except in (b), on which only two mice are shown. On the scans the heads ofthe
mice are directed upwards. The xenografts are indicated by arrows in (a-c) and are located in the side of the mice. In (d) the arrow
indicates the location of the thyroid, which is not blocked to facilitate the orientation of the images.Immunoscintigraphy of SCLC xenografts with anti-NCAM MAb 123C3
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Figure 2 The tumour to tissue ratios in Balb/c nude mice carrying H69 xenografts 7 days after administration of the radiolabelled
anti-NCAM MAbs. The mean values and the standard error of the mean are shown. The ratios for each MAb are all statistically
different from each other (P=0.05, Kruskal-Wallis test). *, 123C3; E, MOCl91; 0, 123A8, E, M6/1.
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Figure 3 The fractions of the injected dose per g of tissue, retained in the various tissues 7 days after administration of the
radiolabelled MAbs to the mice carrying an H69 xenograft. The mean values and the standard error of the mean are shown. The
tumour uptake for each MAb is statistically different from all other MAbs (P = 0.04, Kruskal-Wallis test). The non-tumour uptake
is similar for all anti-NCAM MAbs. *, 123C3; O, MOCl91; 0, 123A8; E, M6/1.
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,ter 1 MAbs, suggesting similar pharmacokinetic beha- other MAbs did not increase with time at both incubation
ir. The control MAb showed very low uptake in the temperatures. This finding suggests that MAb 123C3 is
kour tissue (fraction ID g-' is 3.3%), but a high retention internalised by the tumour cells, whereas MAbs 123A8 and
)lood compared with the cluster 1 MAbs. MOC191 remain at the cell surface. The process of
since MAbs 123C3 and MOC191 had similar immuno- internalisation of MAb 123C3 is slow compared with that
Xivity and affinity, whereas MAb 123A8 had only slightly of MAbs bound to other molecules, for example receptor
er values, these parameters are unlikely to be responsible molecules (Matzku et al., 1986; Press et al., 1989), since only
the difference in tumour uptake between the MAbs. a relatively small fraction of the bound MAbs (<25%) was
refore, other factors must play a more important role in internalised after 2 h of incubation at 37°C.
sing the difference between MAb 123C3 and both other In a similar experiment, internalisation of FITC-labelled
Lbs. MAbs was monitored by confocal laser scanning fluorescence
Ve investigated the possibility of internalisation of the microscopy (CLSM). The results with FITC-labelled MAb
ind MAbs as the cause of the difference in the in vivo 123C3, after removing the surface-bound MAb for visibility
our uptake. Since the cell-surface bound MAbs can be reasons, are shown in Figure 5a. The tumour cells showed
ased by treatment of the cells with a low pH buffer evident cytoplasmic fluorescence in different tomographic
ttzku et al., 1986), whereas internalised antigen-antibody planes, indicating the presence of internalised antibody. The
iplexes are not affected by this treatment, we used this images also showed that treatment of the cells with low pH
perty in a radioimmunossay to measure internalisation. buffer indeed removed the antibody bound to the cell surface
) cells were loaded with 1251-labelled MAbs at 0°C and, very effectively (Figure 5a). In Figure Sb the results of the
sequently, the cells were incubated at 37°C or at 0°C. experiment with FITC-labelled MAb 123A8, without the
ce internalisation is an energy-dependent process, it will treatment with the acidic buffer, are shown. The H69 cells
take place at 0°C. Figure 4 shows that the fraction of showed only fluorescence at the cell surface and failed to
Lb 123C3 that remained associated with the cells after show intracellular fluorescence in any of the planes,
.tment with a low pH buffer increased with longer indicating that this MAb does not induce internalisation of
ibation periods at 37°C, whereas most MAb could be the NCAM-MAb complex.
toved from the cell surface when the cells were incubated Active internalisation of an antigen-MAb complex
)'C. In contrast, the acid-resistant fractions of both the requires adenosine triphosphate (ATP). Therefore, incuba-
tion of the cells at 37°C in the presence of 2-deoxy-D-glucose
and sodium azide, which will deplete the cells of ATP, is
expected to prevent internalisation. Indeed, when H69 cells
were incubated with FITC-labelled MAb 123C3 in the
a presence of these drugs no intracellular fluorescence could
25 - be detected, whereas the binding of the labelled MAb to the
cell surface was not affected (not shown). These results
confirm the notion that the MAb 123C3-NCAM complex is
actively internalised.
We studied the processing of the internalised NCAM-
MAb 123C3 complexes in more detail by electron micro-
123C3 scopy. H69 cells were incubated with MAb 123C3 for 24 h at
37°C, fixed and indirectly stained with an immunogold
conjugate. Using a dose of 1 mg, MAb 123C3 could not
only be detected on the cell surface and in coated pits, but it
was also present intracellularly, in coated vesicles and
multilamellar bodies (Figure 6). This suggests that at least
M6/1 part of the internalised NCAM-MAb 123C3 complexes
0 6 so 1 follows a pathway that is likely to end in the lysosomes.
0 30 60 90 120 150 There were no gold particles found in other parts of the
Time (min) cytoplasm.
b To investigate the fate of the radiolabelled MAbs and
25 - radiolabel after internalisation we incubated 1251-labelled
MAb 123C3, and MAb 123A8 for comparison, with H69
20
cells in culture at 37°C
for various periods. By removing the
unbound antibody from the culture medium we used a fixed
amount of radiolabelled MAb for this experiment. The
15- amount of cell-surface bound and intracellular radiolabel
could be determined separately after treatment with a low pH
10 M0C191
buffer (see above). The cell-surface bound fraction of MAb
-------a ___ OCl91123C3 decreased in time owing to internalisation, whereas the
amount of cell-surface bound MAb 123A8 remained constant
5
123A8 (Figure 7a). The intracellular fraction of MAb 123C3
----- ~~~~~fi~--- ]a increased to 22.3% at 24 h, whereas the intracellular fraction
0 of MAb 123A8 remained low (7.5%), confirming that MAb
0 30 60 90 120 150 123C3 is internalised. However, the amount of surface-bound
Time (min) MAb 123C3 decreased more than was recovered from the
intracellular compartment. The discrepancy may be the result
gure 4 The internalisation of radiolabelled MAb 123C3 by of degradation of the radiolabelled antibody in the lysosomes
69 cells demonstrated by radioimmunoassay. After incubation and subsequent secretion of the radioactive iodine (Press et
the H69 cells with 125I-labelled MAbs the surface-bound MAb al., 1989). To investigate the catabolism of radiolabelled
Dlecules were removed by treating the cells with a low-pH MAbs, free 1251 was determined after precipitation of the
iffer. The mean values and the standard deviation are shown. protein-bound iodine with TCA. The amount of free iodine
Ab 123C3 is represented by squares, MAb M6/1 by circles, s
Ab MOC191 by diamonds and MAb 123A8 by triangles. Filled howed a greater increase
for MAb 123C3 than for MAb
irkers with continuous lines and open markers with dashed 123A8. The results indicate that catabolism at least partly
es represent respectively the experiments done at 37°C and 0°C. explains the loss of cell-associated radioactivity. However,
ie increase of retained MAb 123C3 with longer incubation is despite the degradation of radiolabelled MAb 123C3 and the
mpatible with the internalisation of this MAb. subsequent release of radiolabel, there is still an accumulation
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Figure 5 Confocal laser scanning immunofluorescence images of H69 cells following incubation with FITC-labelled MAbs 123C3
(a) and 123A8 (b). The images represent tomographic sections of 1 gim thickness of the same cell. The white scale bar represents
5/tm. Intracellular fluorescence can be detected in cells incubated with MAb 123C3, but not in cells incubated with MAb 123A8.
The cell shown in (a) was treated with low-pH buffer to improve the visibility of the intracellular fluorescence, representing
internalised MAb 123C3. The cell shown in (b) received no treatment with low-pH buffer and only membrane-associated
fluorescence was present. When treatment with low pH was applied only minimal fluorescence was present at cell membrane, not
suitable for reproduction.
of intracellular radioactivity when using radiolabelled MAb
123C3. In contrast, when radiolabelled MAb 123A8 is
allowed to bind to the cells, there is no intracellular
accumulation of radioactivity.
Discussion
We have investigated the efficacy of three anti-NCAM MAbs
for immunoscintigraphy of H69 SCLC xenografts in nude
mice in order to design new diagnostic tools. The best images
and the highest tumour to tissue ratios were obtained with
MAb 123C3 7 days after administration of this MAb.
Comparison of the biodistribution of the three MAbs on
day 7 revealed that the specific uptake of radiolabelled MAb
123C3 in the tumour was much higher than the two other
anti-NCAM MAbs, whereas the non-specific uptake in
normal tissues was the same for all three MAbs. This
finding was rather unexpected and could not be explained by
differences in binding properties, as the affinities of all MAbs
for the targeted antigen were similar. Furthermore, the
biological activity was not strongly affected by radiolabelling
and the number of binding sites per cell was the same for all
MAbs. A possible explanation for the difference in retention
in tumour tissue between MAb 123C3 and the two other
MAbs could be a specific interaction between this MAb and
NCAM molecules, inducing internalisation of the NCAM-
MAb 123C3 complex into the tumour cells. Indeed,
radiolabelled MAb 123C3, bound to the cell surface, was
internalised in contrast to two other anti-NCAM MAbs.
Immunofluorescence studies confirmed the difference in
interaction of MAbs 123C3 and 123A8 with NCAM.
Electron microscopy findings suggest that the internalisation
pathway of the NCAM-MAb 123C3 complex starts with
endocytosis through coated pits, via multilamellar bodies,
and may finally end in the lysosomes. MAb-induced
internalisation of antigens through coated pits has been
described previously (Matzku et al., 1986; Press et al., 1989.
Internalisation of the NCAM-MAb complex, which was
briefly reported previously by our group (Michalides et al.,
1994), may lead to a long-lasting association of the
radiolabelled MAb with the cell in contrast to non-
internalising MAbs that might easily dissociate from the
cell surface after binding to the antigen. However, it is
necessary for the retention of radioactivity that the 1251_
labelled MAb is not degraded and dehalogenated immedi-
ately after internalisation. Our results show that internalised
radiolabelled MAb 123C3 is only slowly catabolised.
Although the internalisation rate of NCAM-MAb 123C3
complex is relatively slow compared with the fast internalisa-
tion rate of MAbs binding to receptor molecules at the cell
surface (Matzku et al., 1986; Press et al., 1989), the
degradation of 1251-MAb 123C3 is still slower than the
internalisation process resulting in accumulation of radio-
activity in the cell. These results are in agreement with the
finding reported by Press et al. (1989), who showed that slow
internalisation of MAbs is associated with slow degradation.
The fast internalising MAbs followed a pathway through the
tubular endocytic compartment and the lysosomes, leading to
a fast degradation. In contrast, the slow internalising MAbs
showed only limited presence in these cell compartments.
Apparently, antibody molecules may follow several pathways
following internalisation. The result of the slow internalisa-
tion and degradation of MAb 123C3 is the accumulation of
this MAb in tumour cells and the high tumour retention in
vivo, even on day 7 after administration. The in vivo tumour
uptake achieved with MAb 123C3 compared favourably with
those of other MAbs with similar affinity for the targeted
antigen reported in the literature (Boerman et al., 1991;
Waibel et al., 1993). However, the results of the in vitro
studies cannot be directly translated into in vivo results, but
only indicate that there may be a difference in the in vivoImmunoscintigraphy of SCLC xenografts with anti-NCAM MAb 123C3
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Figure 6 H69 cells were incubated with unlabelled MAb 123C3
for 24h at 37°C. Sections were incubated with rat anti-mouse
immunoglobulin and goat anti-rat immunoglobulin labelled with
gold particles. The images show the presence of MAb 123C3
(arrows) on the cell surface, in coated pits and intracellularly, in
coated vesicles and multilamellar bodies. No MAb 123C3 can be
detected in other parts of the cytoplasm.
uptake. Other factors, such as the pharmacokinetic properties
of the conjugate and the interaction of the radiolabelled MAb
with normal tissues, play a role in vivo in determining the
final tumour uptake.
The absence of internalisation after binding of MAb
123A8 to an epitope close to the binding site of MAb 123C3
(Gerardy-Shahn and Eckhardt, 1994) suggests that MAb
123C3 might induce conformational changes of the NCAM
molecule causing internalisation of the Ag-MAb complex. It
is remarkable that the only antibody known to cause a
change in NCAM function, ERIC-1 (Dickson et al., 1990),
binds to the same domain (Gerardy-Shahn and Eckhardt,
1994). The internalisation of NCAM-MAb 123C3 complex
does not induce internalisation of a non-internalising MAb,
which binds to another epitope (unpublished data). The
Figure 7 Internalisation and degradation. H69 cells incubated
with 125I-labelled MAbs 123C3 (M and continuous line) and
123A8 (0 and dashed line) for various time periods. By treating
the cells with a low-pH buffer, the intracellular radioactivity can
be determined separately from the total, cell-associated radio-
activity. The amount of surface-bound and intracellular radio-
activity is shown as a fraction of the total cell-bound radioactivity
(a). The amount of free iodine in the culture medium was
determined by precipitation of the protein-bound radioactive
iodine with 10% TCA. The free iodine is shown as a fraction of
the initial radioactivity (b). The mean values and the s.d. are
shown.
absence of co-internalisation of MAbs is in analogy to the
findings of other investigators (Matzku et al., 1990; Casalini
et al., 1991).
In conclusion, this study suggests that the relatively high
uptake of MAb 123C3 in the tumour can be attributed to
internalisation. Closer attention should be paid to this
property when screening antibodies for immunoscintigra-
phy. Our results with radiolabelled MAb 123C3 justify the
use of this MAb in human studies. However, the binding to
normal human tissues, such as neural tissue and natural killer
cells, may cause unwanted side-effects (Moolenaar et al.,
1990; Schol et al., 1988; Goldman et al., 1984), although
earlier studies with these MAbs did not report neurotoxicity
or leucopenia as side-effects (Goldman et al., 1984; Lashford
et al., 1987).
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